Apel­lis re­ports PhII ALS fail af­ter stop­ping open-la­bel ex­ten­sion in April

Apel­lis and So­bi will dis­con­tin­ue de­vel­op­ment in ALS af­ter their ap­proved rare blood and eye dis­ease drug failed a Phase II study.

The pair was try­ing to see if pegc­eta­coplan, green­light­ed in two dif­fer­ent in­di­ca­tions since 2021, could al­so help pa­tients with the fa­tal neu­rode­gen­er­a­tive dis­ease. But pegc­eta­coplan missed its pri­ma­ry end­point of the “Com­bined As­sess­ment of Func­tion and Sur­vival” rank score af­ter a year, and al­so missed sev­er­al sec­ondary goals.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER